Risk Factor Analysis for the Occurrence of Severe Adverse Effects in Eribulin Treatment
Sign Up to like & getrecommendations! Published in 2022 at "AntiCancer Research"
DOI: 10.21873/anticanres.15858
Abstract: Background/Aim: Eribulin is an effective chemotherapeutic agent for the treatment of metastatic breast cancer and advanced or metastatic soft-tissue sarcomas. However, severe adverse effects (SAEs) occur in 30-40% of the patients, and significantly reduce the… read more here.
Keywords: eribulin treatment; risk factors; occurrence; treatment ... See more keywords